Exact Mass: 296.0943

Exact Mass Matches: 296.0943

Found 135 metabolites which its exact mass value is equals to given mass value 296.0943, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

4-Nitrophenyl-3-ketovalidamine

4-Nitrophenyl-3-ketovalidamine; p-Nitrophenyl-3-ketovalidamine; N-(4-Nitrophenyl)-3-ketovalidamine

C13H16N2O6 (296.1008)

2,3,9,10-Tetrahydroxyberberine

C17H14NO4+ (296.0923)

Dehypoxanthine futalosine

3-[3-(3,4,5-Trihydroxytetrahydrofuran-2-yl)propionyl]benzoic acid

C14H16O7 (296.0896)

(2-Tert-butyl-3-methyl-4,6-dinitrophenyl) acetate

C13H16N2O6 (296.1008)

Tyrosyl-Aspartate

2-{[2-amino-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}butanedioate

C13H16N2O6 (296.1008)

Tyrosyl-Aspartate is a dipeptide composed of tyrosine and aspartate. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

Aspartyl-Tyrosine

3-Amino-3-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}propanoate

C13H16N2O6 (296.1008)

Aspartyl-Tyrosine is a dipeptide composed of aspartate and tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

DHAP(8:0)

[3-(octanoyloxy)-2-oxopropoxy]phosphonic acid

C11H21O7P (296.1025)

DHAP(8:0) is the octanoyl derivative of Dihydroxyacetone phosphate. It is also known as an alkyl-DHAP. This compound is formed by octanoic acid reacting with DHAP. Alkyl-DHAPs are intermediates in the synthesis of ether phospholipids. The initial steps of ether phospholipid biosynthesis take place in peroxisomes. Alkyl-dihydroxyacetonephosphate synthase is the peroxisomal enzyme that actually introduces the ether linkage. Levels of Alkyl-DHAP have been found to be strongly reduced in human fibroblasts derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients. Four other enzymes are known to be involved in the metabolism of acyl-DHAP and alkyl-DHAP. These include: acyl-DHAP/alkyl-DHAP oxidoreductase, DHAP acyltransferase, alkyl-DHAP phosphohydrolase, and a dinitrofluorobenzene-insensitive acyl-DHAP acylhydrolase. Dihydroxyacetone phosphate (DHAP) is a biochemical compound primarily involved in the glycolysis metabolic pathway. DHAP is also the product of the dehydrogenation of L-glycerol-3-phosphate which is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway. Conversely, reduction of glycolysis-derived DHAP to L-glycerol-3-phosphate provides adipose cells with the activated glycerol backbone they require to synthesize new triglycerides. Both reactions are catalyzed by the enzyme glycerol 3-phosphate dehydrogenase with NAD+/NADH as cofactor. DHAP may be referred to as glycerone phosphate in older texts. [HMDB] DHAP(8:0) is the octanoyl derivative of Dihydroxyacetone phosphate. It is also known as an alkyl-DHAP. This compound is formed by octanoic acid reacting with DHAP. Alkyl-DHAPs are intermediates in the synthesis of ether phospholipids. The initial steps of ether phospholipid biosynthesis take place in peroxisomes. Alkyl-dihydroxyacetonephosphate synthase is the peroxisomal enzyme that actually introduces the ether linkage. Levels of Alkyl-DHAP have been found to be strongly reduced in human fibroblasts derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients. Four other enzymes are known to be involved in the metabolism of acyl-DHAP and alkyl-DHAP. These include: acyl-DHAP/alkyl-DHAP oxidoreductase, DHAP acyltransferase, alkyl-DHAP phosphohydrolase, and a dinitrofluorobenzene-insensitive acyl-DHAP acylhydrolase. Dihydroxyacetone phosphate (DHAP) is a biochemical compound primarily involved in the glycolysis metabolic pathway. DHAP is also the product of the dehydrogenation of L-glycerol-3-phosphate which is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway. Conversely, reduction of glycolysis-derived DHAP to L-glycerol-3-phosphate provides adipose cells with the activated glycerol backbone they require to synthesize new triglycerides. Both reactions are catalyzed by the enzyme glycerol 3-phosphate dehydrogenase with NAD+/NADH as cofactor. DHAP may be referred to as glycerone phosphate in older texts.

4-Carboxynevirapine

2-cyclopropyl-10-oxo-2,4,9,15-tetraazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaene-7-carboxylic acid

C15H12N4O3 (296.0909)

4-Carboxynevirapine is a metabolite of nevirapine. Nevirapine, also marketed under the trade name Viramune, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS. As with other antiretroviral drugs, HIV rapidly develops resistance if nevirapine is used alone, so recommended therapy consists of combinations of three or more antiretrovirals. (Wikipedia)

1-iodo-2-methylundecane

C12H25I (296.1001)

1-iodo-2-methylundecane is classified as a member of the Organoiodides. Organoiodides are compounds containing a chemical bond between a carbon atom and an iodine atom

Penicillamine disulfide

2-amino-3-[(1-amino-1-carboxy-2-methylpropan-2-yl)disulfanyl]-3-methylbutanoic acid

C10H20N2O4S2 (296.0864)

Bentazepam

14-phenyl-8-thia-10,13-diazatricyclo[7.5.0.0^{2,7}]tetradeca-1(9),2(7),13-trien-11-one

C17H16N2OS (296.0983)

D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent

rhamnetin 3-rhamninoside

(1E,5R,6S,7S)-5,6,7,8-tetrahydroxy-1-(4-hydroxyphenyl)oct-1-ene-3,4-dione

C14H16O7 (296.0896)

gamma-Aminobutyric acid-betaxanthin

(2S,4E)-4-[(2Z)-2-[(3-carboxypropyl)imino]ethylidene]-1,2,3,4-tetrahydropyridine-2,6-dicarboxylic acid

C13H16N2O6 (296.1008)

methyl 2-[(3-formamido-2-hydroxybenzoyl)amino]-3-hydroxybutanoate

NCGC00180099-02!methyl 2-[(3-formamido-2-hydroxybenzoyl)amino]-3-hydroxybutanoate

C13H16N2O6 (296.1008)

OCP_297.1002_16.5

C14H17ClN2O3 (296.0928)

CONFIDENCE Identification confirmed with Reference Standard (Level 1); INTERNAL_ID 1302

Penicillamine disulfide

C10H20N2O4S2 (296.0864)

Asp Tyr

C13H16N2O6 (296.1008)

(S)-2-(3-ethoxy-4-nitrobenzamido)pentanoic acid

C13H16N2O6 (296.1008)

Asp-tyr

2-[2-amino-3-(4-hydroxyphenyl)propanamido]butanedioic acid

C13H16N2O6 (296.1008)

A dipeptide composed of L-aspartic acid and L-tyrosine joined by a peptide linkage.

Tyr-asp

4-(4-(2-Chlorophenyl)-1-piperazinyl)-4-oxobutanoic acid

C14H17ClN2O3 (296.0928)

Bentazepam

C17H16N2OS (296.0983)

rhamnetin 3-rhamninoside

(1E,5R,6S,7S)-5,6,7,8-tetrahydroxy-1-(4-hydroxyphenyl)oct-1-ene-3,4-dione

C14H16O7 (296.0896)

gamma-Aminobutyric acid-betaxanthin

An iodoalkane that is undecane substituted by an iodo group at position 1 and a methyl group at position 2. Metabolite observed in cancer metabolism.

Tyrosylaspartic acid

C13H16N2O6 (296.1008)

Octanoyl-glycerone 3-phosphate

C11H21O7P (296.1025)

3,3'-Dithiodivaline

C10H20N2O4S2 (296.0864)

Dithiodivaline

C10H20N2O4S2 (296.0864)

TCS1105

C17H13FN2O2 (296.0961)

TCS1105 is a benzodiazepine ligand with agonist for α2-subunit containing GABAA receptors and antagonist for α1-subunit containing GABAA receptors. TCS1105 reduces anxiety-like behavior in mice. TCS1105 enhances offensive behavior and social dominance. TCS1105 blocks Sema3A induced AGC (axonal growth cones) collapse in a concentration-dependent fashion[1][2].